Tipranavir to be Considered for Use in Multi-drug Resistant HIV Infection
Apr 5, 2005 - 9:00:00 AM
Aptivus is a non-peptidic protease inhibitor. The drug is used in combination with other antiretroviral agents in patients previously treated with protease inhibitors.
By FDA advisory committe, [RxPG] The Antiviral Drugs Advisory Committee will meet May 19 to discuss Boehringer Ingelheims NDA for Aptivus (tipranavir).
The committee will consider the HIV therapy for use in patients with multi-drug resistant disease.
Aptivus is a non-peptidic protease inhibitor. The drug is used in combination with other antiretroviral agents in patients previously treated with protease inhibitors.
In clinical trials, use of Aptivus was associated with both gastro-intestinal adverse events and elevated triglycerides.
If approved, Aptivus would be the second marketed non-peptidic PI; Pfizers Viracept (nelfinavir) was approved in 1997.
